MedTrace Logo

Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients

NCT00316407 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2011-02-18

No results posted yet for this study

Summary

The purpose of this study is to determine the effectiveness, safety, tolerability and best dose of Lapatinib (GW572016) in combination with carboplatin and paclitaxel.

Conditions

  • Ovarian Epithelial Cancer Stage III
  • Stage IV Ovarian Cancer
  • Stage IV Breast Cancer

Interventions

DRUG

lapatinib (GW572016)

1000 mg po qd

DRUG

Carboplatin

AUC 2 weekly x 3 of 4 week cycle

DRUG

Paclitaxel

60 mg/m2 weekly x 3 of 4 week cycle

Sponsors & Collaborators

Principal Investigators

  • Saul Rivkin, MD · Swedish Medical Center Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2009-11-30
Completion
2009-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00316407 on ClinicalTrials.gov